Just attended the AGM - Sharing my personal impressionsHi all, here's what I take back from the HEM AGM today:
- The CLI phase 2 study appeared to have been poorly conducted (e.g. no quality of life / functional improvement measurement), and the disappointing results could be due to that, more than ACP1 lack of effectiveness. Seems that management is looking for a way to go for Phase 3 to get the final answer. Safety is not a concern. They think they have enough evidence to go to the FDA.
- Heart function improvement study was a lot clearer in its effectiveness and this is really making a significant difference for critically ill cardiac patients. There was cautious enthusiasm around the possibilities for this one, though directors did not dare say how much revenue could be harvested from this option.
- Pre-Cerv revenues will eventually be distributed to HEM shareholders, though it was unclear to me whether they would spin off another publicly traded company or keep it as a subsidiary. This is still at an early stage anyway.
- TS appeared to be in a real hurry to stop the Q&A session, despite many questions being added to the chat queue. I think he wasn't too proud of the news he shared. Thankfully other directors intervened to make sure Qs were covered.
Overall, I feel like I want to keep my investment going with HEM, although I sense that we'll need a partnership to fund the next studies. I hope that this is possible, because I wasn't impressed with the plans to fund continued operations. They were vague at best.
I'll probably buy if/when the stock drops below 20 cents, because there's still a lot potential for the product itself. I'm just worried about management.
GLTA
-J2B